Amgen dismisses bone density concerns related to its new weight-loss drug [Yahoo! Finance Canada]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance Canada
"The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide," Amgen said, adding that it looks forward to data from its mid-stage study later this year. Shares of Amgen rose 2% in premarket trade after the company's statement. Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along with the results in February. At least four analysts said the concerns were overblown, especially considering the company was conducting a mid-stage study and planned to invest in a larger late-stage trial as well. "While a new safety signal would certainly be (a) cause for alarm on any drug, the truth is, (Amgen) knows a lot more about this molecule than the Street," Piper Sandler analyst Christopher Raymond said in a note. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli) Recommended Stories
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENTPR Newswire
- Ischemic Heart Disease (IHD) Drugs Strategic Research Report 2024: Market to Grow by $1.1 Billion During 2023-2030, Driven by Increasing Demand for Combination Therapies [Yahoo! Finance]Yahoo! Finance
- How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]Yahoo! Finance
- Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) ConverAcquire Media Monitor
- Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 10/30/24 - Beat
AMGN
Sec Filings
- 11/6/24 - Form 4
- 11/6/24 - Form 4
- 11/6/24 - Form 4
- AMGN's page on the SEC website